At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m (1) TP).

Learn from the MHRA about evolving CMC expectations, submission criteria, and initiatives for streamlining approval routes for mRNA platforms. Continuous processing: Optimizing efficiency & ...

Stay ahead in the booming mRNA market, projected to reach $63.28 billion by 2025, with the 3 rd mRNA Process Development & Manufacturing Summit 2025 - Europe’s premier industry-focused forum dedicated ...

The market for mRNA vaccines has experienced a surge fueled by the global rollout of the COVID-19 vaccines, and the potential of mRNA technology in public health opens a new frontier in medical ...

Foundation-funded project targets infectious bronchitis and infectious laryngotracheitis viruses.

In principle, mRNA vaccines are ideal for health emergencies as they can be quickly mass produced using a template. The problem is that current cell-based template production methods take too long, ...

They are like the architects of our body: messenger ribonucleic acids, or mRNA for short. They contain detailed blueprints for proteins, which are read and translated by their “colleagues”, the ...

Frankfurt: German agrichemical giant Bayer confirmed to AFP on Wednesday that it was suing American pharmaceutical firms ...

Researchers have used an experimental mRNA therapy to make old immune cells in mice behave as if they were young again, ...